Rexpression of HLA class I antigens and restoration of antigen‐specific CTL response in melanoma cells following 5‐aza‐2′‐deoxycytidine treatment
暂无分享,去创建一个
[1] F. Garrido,et al. Molecular strategies to define HLA haplotype loss in microdissected tumor cells. , 2000, Human immunology.
[2] F. Garrido,et al. High frequency of altered HLA class I phenotypes in laryngeal carcinomas. , 2000, Human immunology.
[3] P. Stern,et al. Multiple mechanisms underlie HLA dysregulation in cervical cancer. , 2000, Tissue Antigens.
[4] G. Fleuren,et al. Multiple Genetic Alterations Cause Frequent and Heterogeneous Human Histocompatibility Leukocyte Antigen Class I Loss in Cervical Cancer , 2000, The Journal of experimental medicine.
[5] P. Dalerba,et al. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[6] A. Concha,et al. Microsatellite instability analysis in tumors with different mechanisms for total loss of HLA expression , 2000, Cancer Immunology, Immunotherapy.
[7] Thierry Boon,et al. DNA Methylation Is the Primary Silencing Mechanism for a Set of Germ Line- and Tumor-Specific Genes with a CpG-Rich Promoter , 1999, Molecular and Cellular Biology.
[8] D. Templeton,et al. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. , 1999, Journal of immunology.
[9] P. Slootweg,et al. Mutation in the β2m gene is not a frequent event in head and neck squamous cell carcinomas , 1999 .
[10] P. Dalerba,et al. Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family. , 1999, Cancer research.
[11] M. R. Oliva,et al. A new beta 2 microglobulin mutation found in a melanoma tumor cell line. , 1999, Tissue antigens.
[12] P. Coulie,et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 , 1999, International journal of cancer.
[13] P. Cony-Makhoul,et al. Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha. , 1998, Blood.
[14] F. Brasseur,et al. Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. , 1998, Tissue antigens.
[15] D. Hicklin,et al. beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. , 1998, The Journal of clinical investigation.
[16] H. Ploegh. Viral strategies of immune evasion. , 1998, Science.
[17] R. Tampé,et al. Constitutive transduction of peptide transporter and HLA genes restores antigen processing function and cytotoxic T cell‐mediated immune recognition of human melanoma cells , 1998, International journal of cancer.
[18] Robert Tampé,et al. Down‐regulation of the MHC class I antigen‐processing machinery after oncogenic transformation of murine fibroblasts , 1998, European journal of immunology.
[19] N. Hayward,et al. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. , 1997, Cancer research.
[20] S. Hattman,et al. Escherichia coli OxyR modulation of bacteriophage Mu mom expression in dam+ cells can be attributed to its ability to bind hemimethylated Pmom promoter DNA. , 1997, Nucleic acids research.
[21] F. Oesch,et al. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma , 1997, International journal of cancer.
[22] B. Drénou,et al. CpG methylation patterns in the 5' part of the nonclassical HLA-G gene in peripheral blood CD34+ cells and CD2+ lymphocytes. , 1997, Tissue antigens.
[23] P. Stern,et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. , 1997, Immunology today.
[24] F. Garrido,et al. Methylated CpG points identified within MAGE‐1 promoter are involved in gene repression , 1996, International journal of cancer.
[25] R. Versteeg,et al. Lack of class I HLA expression in neuroblastoma is associated with high N-myc expression and hypomethylation due to loss of the MEMO-1 locus. , 1996, Oncogene.
[26] O. de Backer,et al. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[27] K. Klaamas,et al. IgG immune response to Helicobacter pylori antigens in patients with gastric cancer as defined by ELISA and immunoblotting , 1996, International journal of cancer.
[28] T. Elliott. Tapping into tumours , 1996, Nature Genetics.
[29] R. Fauchet,et al. Methylation status and transcriptional expression of the MHC class I loci in human trophoblast cells from term placenta. , 1995, Journal of immunology.
[30] W. Bodmer,et al. Immune surveillance in colorectal carcinoma , 1995, Nature Genetics.
[31] X. Sastre,et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection , 1995, European journal of immunology.
[32] W. Bodmer,et al. Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[33] C. Meijer,et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas , 1994, The Journal of experimental medicine.
[34] P. Stern,et al. Natural history of HLA expression during tumour development. , 1993, Immunology today.
[35] D. McFarlin,et al. Regulation of MHC class I and beta 2-microglobulin gene expression in human neuronal cells. Factor binding to conserved cis-acting regulatory sequences correlates with expression of the genes. , 1993, Journal of immunology.
[36] J. Yewdell,et al. Identification of human cancers deficient in antigen processing , 1993, The Journal of experimental medicine.
[37] A. Rustgi,et al. Suppression of MHC class I gene expression by N‐myc through enhancer inactivation. , 1989, The EMBO journal.
[38] P. Pontarotti,et al. CpG islands and HTF islands in the HLA class I region: investigation of the methylation status of class I genes leads to precise physical mapping of the HLA-B and -C genes. , 1988, Nucleic acids research.
[39] P. V. van Helden,et al. Hypomethylation of DNA in pathological conditions of the human prostate. , 1987, Cancer research.
[40] P. Altevogt,et al. Immunoresistant metastatic tumor variants can re‐express their tumor antigen after treatment with DNA methylation‐inhibiting agents , 1986, International journal of cancer.
[41] J. Strominger,et al. Evidence for a shared HLA-A intralocus determinant defined by monoclonal antibody 131 , 1985, The Journal of experimental medicine.
[42] C. Milstein,et al. Stimulation of HLA‐A,B,C by IFN‐alpha. The derivation of Molt 4 variants and the differential expression of HLA‐A,B,C subsets. , 1985, The EMBO journal.
[43] H. Orr,et al. Isolation of HLA locus-specific DNA probes from the 3'-untranslated region. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[44] E. E. Max,et al. CG dinucleotide clusters in MHC genes and in 5' demethylated genes. , 1984, Nucleic acids research.
[45] R. Roeder,et al. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. , 1983, Nucleic acids research.
[46] C. Barnstable,et al. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis , 1978, Cell.
[47] E. Scarano,et al. DNA Methylation , 1973, Nature.
[48] M. R. Oliva,et al. β2-microglobulin gene mutation is not a common mechanism of HLA class I total loss in human tumors , 2000, International journal of clinical & laboratory research.
[49] F. Garrido,et al. The HLA crossroad in tumor immunology. , 2000, Human immunology.
[50] J. G. van den Tweel,et al. Mutation in the beta 2m gene is not a frequent event in head and neck squamous cell carcinomas. , 1999, Human immunology.
[51] F. Garrido,et al. HLA class I antigens in human tumors. , 1995, Advances in cancer research.
[52] P. Le Bouteiller. HLA class I chromosomal region, genes, and products: facts and questions. , 1994, Critical reviews in immunology.
[53] H. Zinszner,et al. DNA binding of regulatory factors interacting with MHC‐class‐I gene enhancer correlates with MHC‐class‐I transcriptional level in class‐I‐defective cell lines , 1991, International journal of cancer. Supplement = Journal international du cancer. Supplement.
[54] S. Ferrone,et al. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. , 1991, The Journal of clinical investigation.
[55] A. Townsend,et al. Antigen recognition by class I-restricted T lymphocytes. , 1989, Annual review of immunology.